Abstract 241P
Background
The aims of this study were to investigate the genetic alternations of locally advanced cervical cancer and to elucidate the associations among clinico-pathological factors, genomic alterations and clinical outcomes of the patients receiving concurrent chemo-radiotherapy (CCRT). We performed the targeted sequencing for somatic mutations across the hotspot regions of 50 cancer-related genes using biopsy specimens.
Methods
Seventy-six patients diagnosed as FIGO Stage III to IVA cervical cancer underwent radiation therapy or CCRT at National Cancer Center Hospital between January 2008 and December 2017. All the patients received external beam radiation therapy and brachytherapy. The most of chemotherapy regimen was cisplatin. Genomic DNAs extracted from formalin-fixed and paraffin-embedded tumor tissues were subjected to the analysis using an Ion AmpliSeq TM Cancer Hotspot Panel v2. Six patients were disqualified from this study because of low quality DNA. Oncogenic or pathogenic variants registered in the OncoKB and the ClinVar databases were defined as mutations. In the present study, gene aberrations with evidence levels 1A-3A were judged as actionable mutation for molecular targeted drugs. HPV infection was detected by in-situ hybridization and genotypes were determined by Sanger sequencing.
Results
Seventy patients were enrolled in this study. Sixty-five patients (93%) had squamous cell carcinoma. Pathogenic mutations were detected in 47 cases (67%); frequencies of gene alterations in PIK3CA (51%), FBXW7 (10%), PTEN (7.1%) and TP53 (5.7%). The clinical factor associated with poor survival was the tumor diameter. Cox regression analysis showed the tumor diameter larger than 70mm were associated with shorter progression-free survival (PFS) (Hazard ratio = 2.96, P = 0.0048) in multivariate analysis. Patients infected without HPV16/18 had poor PFS than those with HPV 16/18 (Log-rank P = 0.025). TP53 mutants were correlated with poor PFS (Log-rank P = 0.044). Thirty-seven patients (53%) have actionable genomic alternations.
Conclusions
Larger tumor diameter, non HPV16/18 and TP53 mutants correlated with worse outcomes to CCRT in the Japanese patients with locally advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract